Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. II. Clinical and serologic observations of response to revaccination with calf lymph vaccine.
Revaccination with standard calf lymph vaccine was performed on 26 children who had received a primary vaccination with an attenuated smallpox vaccine, CVI-78, and 22 children who had received primary vaccination with standard calf lymph. Revaccination resulted in a vesicular reaction in 96 percent of those who had been vaccinated previously with CVI-78 and 73 percent of those vaccinated previously with standard calf lymph. All children had a positive hemagglutination-inhibition (HI) antibody titer either after primary vaccination or revaccination. Only 65 percent of those initially vaccinated with CVI-78 vaccine had positive neutralizing antibodies after revaccination. All children who received primary vaccination with standard calf lymph had postrevaccination neutralizing antibodies. The children who had neither a dermal nor a serologic response after primary vaccination responded as primary vaccinees on challenge with standard calf lymph.
D000818:Animals; D000914:Antibodies, Viral / Q000032:analysis; D000917:Antibody Formation; D001768:Blister / Q000209:etiology; D002417:Cattle; D002675:Child, Preschool; D005500:Follow-Up Studies; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007223:Infant; D009500:Neutralization Tests; D012867:Skin / Q000276:immunology; D012899:Smallpox / Q000517:prevention & control*; D012900:Smallpox Vaccine / Q000009:adverse effects; D014481:United States; D014611:Vaccination / Q000379:methods; D014613:Vaccines, Attenuated / Q000009:adverse effects
D000914:Antibodies, Viral; D012900:Smallpox Vaccine; D014613:Vaccines, Attenuated